Syros Gets ‘Tyme’ To Bring Lead Candidate To Pivotal Readout

 
• By Joseph Haas

Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Time was a primary obstacle for Syros, until it agreed to merge with Tyme

More from Deals

More from Business